DegarelixGnRH antagonist
Degarelix blocks the pituitary GnRH receptor and rapidly suppresses signals that stimulate testosterone production. Its role in prostate-cancer care is distinct from hormone stimulation for fertility or wellness.
What is Degarelix?
Degarelix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in advanced prostate cancer. It suppresses testosterone through the pituitary hormone pathway. 1 2
How it works
Direct GnRH receptor blockade reduces luteinising hormone and then testosterone without the initial stimulation associated with a GnRH agonist. 2
Effects studied
What does the evidence show?
Prostate-cancer hormone-suppression trial
Blocking rather than stimulating the receptor
Degarelix is a gonadotropin-releasing hormone antagonist. It blocks GnRH receptors in the pituitary, reducing luteinising hormone and then testosterone. This differs from GnRH agonists, which initially stimulate the receptor before sustained exposure suppresses it.
Why the early pattern can matter
Some prostate cancers depend on androgen signalling. An initial testosterone surge can be clinically undesirable in certain advanced-disease situations. Degarelix avoids that agonist-type flare, which is a specific pharmacological advantage rather than a claim that every cancer outcome will be better.
What the comparative trial establishes
The retained trial compared degarelix with leuprolide and assessed testosterone suppression. Achieving the hormone target is important, but it should not be substituted for overall survival, symptom relief or cardiovascular safety. Those outcomes need their own data and appropriately selected comparisons. 1
The effects of low testosterone remain relevant
Injection-site reactions can affect tolerability. Longer-term androgen deprivation can also affect bone, metabolism, sexual function and everyday wellbeing, regardless of how suppression is achieved. Those consequences and the wider cancer plan need to be weighed alongside the rapid hormonal response. 2
Safety & status
Injection-site reactions and the consequences of low testosterone matter. Bone, metabolic and sexual effects require attention during androgen-deprivation treatment. 2
Country and product status
Product indications and availability vary by country; current EU and Swiss status has not been independently checked for this draft.
Frequently asked questions
Why is it described as avoiding a flare?
It blocks the receptor directly rather than first stimulating it, avoiding the initial hormonal rise characteristic of GnRH agonists. 2
Does faster testosterone suppression prove longer survival?
No. Those are different outcomes and require their own clinical comparisons. 1
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
- Retained source reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.